SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid a steep selloff, with traders pointing to scheduled lockup expirations and potential insider-share supply, alongside concerns about its IPO valuation, growth and ability to scale. The debate pits bearish calls for further declines against dip-buyers who remain bullish on Cerebras AI-inference technology and long-term demand.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided quarterly results and upbeat 2027 EBITDA outlook have driven a sharp rally, with traders debating whether short covering could extend the move. Bulls see improving steel operations and prices, while skeptics question whether the outlook can overcome the companys debt and reliance on favorable steel markets; some also warn the rally could fade.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as traders focus on financing costs, debt concerns and doubts about the sectors business models, with CoreWeaves credit worries adding to contagion fears. The community is split on whether sharp rebounds are durable or bull traps: bulls point to Nebiuss comparatively stronger balance sheet and long-term compute demand, while bears question the capital intensity and path to profitability.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs Buy upgrade after a sharp selloff is driving attention, but traders are split after the initial pop faded: some see an oversold buying opportunity, while others remain concerned about CoreWeaves heavy debt and financing costs.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp pullback despite strong operating results is fueling debate, with traders frequently blaming insider share sales and managements failure to announce a fresh buyback; some also cite an analyst downgrade and regional macro concerns. Bears see continued weakness, while bulls argue the selloff has made the growing e-commerce and fintech business more attractive.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus pancreatic cancer IMPACT trial completed enrollment after expanding from 12 to 48 patients, which traders view as a sign of strong clinical-site and patient interest; the results are still pending. Attention also centers on the FDA-cleared expansion of its recurrent glioblastoma REGAIN trial and anticipated clinical updates, with mostly bullish reactions tempered by uncertainty about what the larger studies will show.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XEs steep selloff and search for a bottom dominate the discussion, with traders attributing pressure to post-IPO selling, bearish analyst coverage, and weakness across nuclear stocks. Some see Amazons backing and potential SMR demand from data centers as a long-term positive, while others remain concerned that commercialization is years away.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

FDA expanded ANKTIVA plus BCG to cover papillary-only BCG-unresponsive bladder cancer, broadening its potential market; traders also focused on long-term Phase 3 data showing durable responses and bladder-sparing outcomes. Despite bullish views on the commercial opportunity, the shares sold off, with the community debating a sell-the-news reaction and broader biotech weakness versus options-related or short-selling pressure, while some remain cautious about revenue growth and dilution.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is drawing attention ahead of its Q3 earnings report as shares retreat amid a broader tech and AI selloff. Traders are split over whether strong ad performance and Muse AI momentum can justify heavy AI spending, with capex and returns on that investment central to expectations for the report.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are focused on Disneys recent rebound and repeated tests of resistance, debating whether it can break out or will keep slipping back into its trading range. Bullish posts point to buyers defending the pullback, while bearish traders cite failed attempts to hold gains and downside options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The move appears tied to momentum trading and short-squeeze speculation, with traders citing a small float and limited share availability to borrow. A Velaris acquisition and financing are also mentioned, but that catalyst is not independently corroborated.

High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

Alaunos’ $350 Million Velaris Deal Targets New Frontier in Pulmonary Hypertension

Alaunos Therapeutics (NASDAQ:TCRT) completed its acquisition of Velaris Therapeutics and secured approximately $350 million in gross private-placement proceeds, setting up an aggressive push into pulmonary arterial hypertension (PAH) with a clinical pipeline targeting multiple disease-driving pathways.

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million.
Senti Biosciences (NASDAQ:SNTI) stockread more...

Wall Street’s Next Movers

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million.
Circle8 Group (NASDAQ:CIRC) stock movedread more...

Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.read more...

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million.
Picard Medical (AMEX:PMI) stock movedread more...

Market Moves Investors Can’t Ignore

Five companies, six developing stories, including Totaligent (OTCID:TGNT), Fermi America (NASDAQ:FRMI), Advanced Micro Devices (NASDAQ:AMD), Alaunos Therapeutics (NASDAQ:TCRT), BIO-key International (NASDAQ:BKYI), and Bumble (NASDAQ:BMBL).

Paragon Recruits Apogee’s Former Leaders After $10.9 Billion AbbVie Buyout

Alaunos Therapeutics (NASDAQ:TCRT) has completed its acquisition of Velaris Therapeutics, a privately held biotech developing treatments for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. Velaris is the ninth company built around assets discovered by Paragon and the first launched with support from Paragon’s expanded leadership team.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million.
Scinai Immunotherapeutics (NASDAQ:SCNI) stock roseread more...

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

Alaunos Therapeutics Inc

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Researchers observed treatment-linked improvements in body composition, including lower fat mass and relatively higher lean mass.</li><li>The drug candidate was associated with lower fasting insulin, better insulin resistance readings and signs of reduced fatty liver activity.</li><li>Alaunos said it is optimizing the drug’s formulation after some dose-related reductions in water intake affected part of the study data.</li></ul><p>Alaunos Therapeutics (TCRT) shared new preclinical data for ALN1003, its experimental obesity drug candidate, on Tuesday. The oral treatment is being developed for obesity and related metabolic disorders without using hormones or incretin-based mechanisms.</p><p>The TCRT stock was, however, down 1.66% at the time of writing.&nbsp;</p><h2 class="st-heading-2">Study Combined Findings From Multiple Obesity Trials</h2><p>The company combined data from two earlier non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies reported on March 2 and May 18, along with new cross-study analyses released in a presentation published on Tuesday. The studies looked at how ALN1003 affected several key markers linked to obesity and metabolic disorders.</p><p>According to the company, the treatment was associated with lower body weight and reduced food intake. Researchers also observed lower fat mass and relatively higher lean mass levels in treated mice.&nbsp;</p><h2 class="st-heading-2">Improvements Across Metabolic Health Markers</h2><p>The data also pointed to improvements in insulin resistance and liver-related markers. Alaunos said treated mice showed lower fasting insulin levels and better HOMA-IR readings, which are commonly used to measure insulin resistance.</p><p>Researchers also reported signs of improved liver health. This included “lower liver weight, lower liver-injury and cholestatic enzymes and qualitative liver histology findings consistent with lower hepatic steatosis,” the company said.</p><p>Alaunos added that metabolic syndrome affects multiple organ systems in the body, and believes “a profile that engages several of these systems may be important for future therapeutic approaches.”&nbsp;</p><h2 class="st-heading-2">Mouse Studies Showed Weight, Metabolic, Liver Improvements</h2><p>Alaunos said the two DIO mouse studies evaluating ALN1003 showed improvements across many obesity and metabolic health markers. In the longer 48-day study, the drug was linked to lower body weight, improved insulin resistance markers, healthier fat-related hormone signaling and signs of better liver health.</p><p>In the shorter 18-day study, researchers tested multiple dose levels and observed changes in body weight, fat loss, glucose, cholesterol and liver weight.</p><h2 class="st-heading-2">TCRT Stock: What Does Retail Think?</h2><p>Despite the study results, retail sentiment on Stocktwits turned “bearish” from “neutral” a day ago.&nbsp;</p><p>Year-to-date, the&nbsp;<a href="https://stocktwits.com/symbol/TCRT">TCRT stock</a> has fallen nearly 28%.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Alaunos Therapeutics (TCRT) shared new preclinical data for ALN1003, its experimental obesity drug candidate. 

Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results

Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.16
Prev Close	$2.63
Open	$3.01
Dividend Yield	0.00%
50-Day Moving Average	$1.53
Beta	0.90
Avg. Volume	2.38M
PE Ratio	-1.35

52-Week High	$4.50
52-Week Low	$0.719
Market Capitalization	$7.7M
EPS (Annual)	-$2.20
Price to Book	10.03
Revenue Per Employee	$5,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TCRT Fundamentals